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Abstract
High-dose use of benzodiazepines (BZDs) and Z-drugs was found to be associated with adult attention deficit/hyperactivity 
disorder (ADHD) and multidomain cognitive deficits, but the interplay between these factors and its effect on quality of life 
(QoL) is unclear. We explored (a) whether cognitive dysfunction differs in high-dose BZD/Z-drug users with and without 
adult ADHD and (b) the impact of cognitive deficits and adult ADHD on QoL in this substance-use disorder (SUD). From 
January 2015 to December 2019, we recruited 207 high-dose BZD/Z-drug users seeking treatment. We assessed the pres-
ence of adult ADHD with a screening tool, which was validated in SUD patients, and collected demographic, clinical and 
QoL data from the 76 included patients. A neuropsychological battery explored five cognitive domains. We found that: (a) 
screening for adult ADHD was frequently positive; (b) Short Form-36 (SF-36), a self-administered QoL questionnaire, was 
worse than the general population and worse in patients positive (ADHD+) vs. those negative (ADHD−) to ADHD screen-
ing tool; (c) executive function was significantly worse in ADHD+ than ADHD− patients; (d) some SF-36 dimensions were 
negatively influenced by executive dysfunction; (e) multivariate analysis showed an interplay between adult ADHD and 
cognitive dysfunction in worsening QoL. We documented a complex interplay between adult ADHD, cognitive dysfunc-
tion and QoL in high-dose BZD/Z-drug users. Assessing adult ADHD, neuropsychological measures and QoL may offer a 
full scenario of these patients, who are frequently impaired in everyday activities. Future research should explore whether 
pharmacological treatment might improve cognitive dysfunction and QoL in this SUD.
Keywords Attention-deficit/hyperactivity disorder (ADHD) · Benzodiazepine (BZD) · Cognition · Patient-centered 
outcomes · Quality of life (QoL) · Substance-use disorder (SUD)
Introduction
Benzodiazepines (BZDs) and related Z-drugs (i.e., zolpi-
dem, zopiclone, eszopiclone, and zaleplon) are positive 
allosteric modulators of the gamma-amino-butyric acid type 
A receptor that are prescribed for the treatment of anxiety 
and insomnia (Soyka 2017). Despite guidelines stipulate that 
BZDs and Z-drugs should be used for short periods of time, 
their long-term use is reported in 6–76% and dependence in 
3–4% of patients (Kurko et al. 2015; Soyka 2017).
The estimated prevalence of long-term use of BZDs and 
Z-drugs at high doses ranges from 0.06 to 0.16% of the pop-
ulation in Europe (Ohayon and Lader 2002; Petitjean et al. 
2007). We have previously documented that high-dose BZD 
and Z-drug use (i.e., ≥ 5 times the recommended maximum 
daily dose; Liebrenz et al. 2015) is associated with worse 
quality of life (QoL; Tamburin et al. 2017b) and cognitive 
dysfunction involving multiple domains (Federico et al. 
2017).
Attention-deficit/hyperactivity disorder (ADHD) is a 
neurodevelopmental disorder that has 6–9% prevalence in 
children (Polanczyk and Rohde, 2007), and may persist 
in adults with 2.5–5% prevalence (Volkow and Swanson, 
Fabio Lugoboni and Stefano Tamburin have shared senior 
authorship.
 * Stefano Tamburin 
 stefano.tamburin@univr.it
1 Department of Neurosciences, Biomedicine and Movement 
Sciences, University of Verona, Piazzale Scuro 10, 
37134 Verona, Italy
2 Addiction Medicine Unit, Department of Medicine, Verona 
University Hospital, Piazzale Scuro 10, Verona, Italy
1110 A. Federico et al.
1 3
2013; Bonvicini et al. 2016). Adult ADHD has been reported 
to be more common in people with SUD than the general 
population (van Emmerik-van Oortmerssen et al. 2012; 
van de Glind et al. 2014), and to be associated with worse 
SUD course (Mariani and Levin 2007; Liao et al. 2017; 
Rodríguez-Cintas et al. 2018; Lugoboni et al. 2020a) and 
reduced QoL in the general population (Ahnemark et al. 
2018) and in patients with SUD (Liao et al. 2017).
Routine assessment of ADHD in adult people with SUD 
is helpful but may be complex because of the long diagnostic 
interview that should include a retrospective investigation 
of childhood symptoms (Tamburin et al. 2017c) and differ-
ent diagnostic criteria across DSM versions (van de Glind 
et al. 2013). A validated screening tool for adult ADHD with 
good accuracy and short application time might be used in 
the clinical setting (van de Glind et al. 2013). We have pre-
viously documented that a screening test for adult ADHD 
may be positive in approximately one-third of high-dose 
BZD and Z-drug users (Tamburin et al. 2017c), and that 
adult ADHD is associated with worse QoL in this population 
(Lugoboni et al. 2020b).
ADHD is associated with substantial deficits across a 
variety of cognitive domains, including working memory, 
reaction time variability, response inhibition, intelligence/
achievement, planning/organization, and vigilance (Pievsky 
and McGrath 2018). Multidomain cognitive deficits in adult 
ADHD have been suggested to be explained by impairment 
of basic processes (i.e., processing speed and distractibility; 
Butzbach et al. 2019) and sustained attention (Tucha et al. 
2017).
Data on the interaction between adult ADHD, cogni-
tion and QoL in high-dose BZD/Z-drug users are lacking. 
This paper is aimed to answer two questions. The first is 
whether cognitive dysfunction differs in high-dose BZD and 
Z-drug users with and without adult ADHD. The second is 
to explore the impact of cognitive deficits and adult ADHD 
on QoL in this SUD population. To these aims, we recruited 
a group of high-dose BZD/Z-drug users seeking treatment, 
assessed the presence of adult ADHD with a screening tool, 
which was validated in SUD patients (van de Glind et al. 
2013), and collected demographic, clinical, cognitive and 
QoL data. Since coexisting SUD to other drugs, neurologic 
or major psychiatric disorders might influence both cogni-
tive function and QoL, these conditions were ruled out.
Methods
Patients
We recruited 207 high-dose BZD or Z-drug users (94 men 
and 113 women), who were admitted to the Department 
of Medicine, Addiction Medicine Unit, Verona University 
Hospital, Italy from January 2015 to December 2019 for 
detoxification with slow subcutaneous infusion of flumazenil 
(Tamburin et al. 2017a).
The inclusion criteria were: (a) age > 18 years, (b) formal 
education ≥ 8 years, (c) Italian as mother language, (d) nor-
mal or corrected-to-normal vision, (e) no hearing loss, (f) no 
acute drug intoxication, (g) normal overall cognition docu-
mented by a Mini Mental State Examination score > 24/30, 
(h) no neurological diseases that might interfere with cogni-
tion, (i) no major psychiatric disorders, and (j) no concur-
rent alcohol use or other SUD (Federico et al. 2017). The 
diagnosis of psychiatric disorders was based on screening 
tests, diagnostic interviews, and previous psychiatric evalu-
ations, when available. Among major psychiatric disorders, 
anxiety disorders and mild depression were not considered 
as exclusion criteria because they are common in patients 
taking BZDs/Z-drugs and we ruled out only more severe 
psychiatric conditions (i.e., severe psychoses and personality 
disorders). After selection, 76 patients (34 men, 42 women; 
age 43.2 ± 10.0 years, median 43; education 12.1 ± 3.3 years, 
median 13) were included (Fig. 1).
High-dose BZD/Z-drug dependence was defined accord-
ing to DSM-IV-TR criteria, with use lasting > 6 months, a 
daily dosage ≥ 5 times the recommended maximum intake 
(i.e., ≥ 50 mg of daily diazepam dose equivalent, DDDE), 
and/or otherwise problematic use of BZDs/Z-drugs, such 
as mixing molecules, escalating dosage, obtaining them by 
illegal means and using them to enhance the effect of other 
substances (Liebrenz et al. 2015; Tamburin et al. 2017a, c).
We collected and analyzed demographic (sex, age, educa-
tion: years), and clinical variables (BZD/Z-drug active prin-
ciple, BZD/Z-drug dosage: DDDE, mg; BZD/Z-drug use 
duration: months; tobacco smoke; depression; anxiety). The 
dosage of BZD/Z-drug was based on patient’s self-report.
The study was conducted according to the Declaration 
of Helsinki and approved by the Ethics Committee of the 
Provinces of Verona and Rovigo based at Verona University 
Hospital (approval ID: 683CESC). All patients gave written 
informed consent for participation to the study and for data 
to be published. All the collected data were anonymized 
with a coding procedure.
Adult ADHD screening
Before starting detoxification, patients were screened for 
adult ADHD with the self-administered World Health 
Organization Adult six-question ADHD Self-Report Scale 
version 1.1 (ASRS v1.1) Symptom Checklist Part A (Kes-
sler et al. 2005). The ASRS v1.1 Symptom Checklist Part A 
with a cutoff ≥ 4 was reported to have good sensitivity and 
k and very high specificity and total classification accuracy 
(Kessler et al. 2005; Tamburin et al. 2017c) and to represent 
a sensitive screener for identifying possible ADHD patients 
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with very few missed cases in patients with SUD (van de 
Glind et al. 2013).
Depression and anxiety measures
The Beck Depression Inventory II (BDI-II), a 21-item self-
administered questionnaire (score 0–3 for each item, cutoff 
for moderate to severe depression 28), was used to meas-
ure the severity of depressive symptoms during the previ-
ous 2 weeks (Federico et al. 2017). The State Trait Anxi-
ety Inventory form Y (STAI-Y), which is composed of two 
20-item self-applied questionnaires, was used to measure 
state and trait anxiety. Each STAI-Y item is scored on a 1–4 
Likert-type format, and the cutoff for mild anxiety is 40 
(Federico et al. 2017).
Neuropsychological evaluation
Before detoxification, patients underwent a neuropsycho-
logical battery to explore verbal, visuospatial and working 
memory, attention, and executive function (Federico et al. 
2017; Cecchini et al. 2019). For each cognitive domain, 
we chose a test with available normal distribution of the 
normative data to calculate Z-scores (see “Statistical analy-
sis” section).
Verbal memory was assessed with the Italian versions 
of the Digit Span Forward Test (DSFT), which measures 
short-term memory. For DSFT, subjects are asked to repeat 
progressively longer digit series starting from three up to 
the longest series they can remember (Monaco et al. 2013).
Visuospatial memory was assessed with the Rey–Oster-
rieth Complex Figure Test (ROCF), where subjects are asked 
to copy a complex bidimensional figure (immediate recall) 
and then redraw it after a 10-min delay (delayed recall; Caf-
farra et al. 2002).
Working memory was assessed with the Digit Span Back-
ward Test (DSBT), which is the same as DSFT, but subjects 
are asked to recall the digit series in reverse of the presented 
order (Monaco et al. 2013).
Attention was assessed with the Trail Making Test Part A 
(TMT-A), which explores selective attention and visuospa-
tial exploration, by asking the subject to draw lines sequen-
tially connecting 25 encircled numbers (Amodio et al. 2008).
Executive function was evaluated with the Trail Making 
Test Part B (TMT-B), which is similar to TMT-A, except 
that the task evaluates mental flexibility and task switching 
Fig. 1  Flow diagram of the 
study and reasons for patients’ 
exclusion
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by asking the subjects to alternate between numbers and 
letters (Amodio et al. 2008).
QoL measures
At admission, before starting detoxification, patients under-
went two self-administered QoL questionnaires, namely the 
Short Form-36 (SF-36) and the General Health Question-
naire-12 (GHQ-12).
The SF-36 is a generic QoL scale composed of 36 items 
that are grouped into 8 dimensions: physical functioning 
(PF), role physical (RP), bodily pain (BP), general health 
(GH), vitality (VT), social functioning (SF), role emotional 
(RE), mental health (MH), with scores ranging from 0 (worst 
score) to 100 (best score) for each dimension (Brazier et al. 
1992).
The GHQ-12 explores psychological health and is com-
posed of 12 questions on mood states over the previous 
2 weeks (Goldberg and Hillier 1979). GHQ-12 was scored 
on a two-point scale, resulting in 0–12 total score range with 
higher values indicating more severe psychological distress 
(Goldberg and Hillier 1979), and a cutoff value of ≥ 4 (Pic-
cinelli et al. 1993).
Statistical analysis
All tests were carried with the IBM SPSS version 20.0 
statistical package. The normality of variable distribu-
tion was analyzed with the Skewness–Kurtosis test. The 
Pearson’s χ2 test was used for categorical variables. The 
unpaired t test and the non-parametrical Mann–Whitney U 
test were used for continuous variables. Neuropsychologi-
cal scores were reported as Z-scores according to the for-
mula: Z-score = (measured value − mean value according to 
age and/or education)/standard deviation according to age 
and/or education. Negative and positive values indicated 
worse and better performance than the normal population, 
respectively. Z-scores were computed for tests with normal 
distribution in the normative sample, i.e., DSFT and TMT-
A/B time (s), DSBT, ROCF delayed recall (Carlesimo et al. 
2002; Mondini et al. 2011; Monaco et al. 2013). The poten-
tial confounder effect of covariates (sex, age, education, 
DDDE, BZD/Z-drug use duration, depression, anxiety) on 
neuropsychological outcomes was explored with a multi-
variate generalized linear model (Federico et al. 2017). Cor-
relations between neuropsychological and SF-36 measures 
were explored with the Spearman’s ρ correlation coefficient. 
Multivariate backward linear regression model analysis was 
applied to SF-36 dimensions (continuous dependent varia-
bles). Logistic regression model analysis was used for GHQ-
12 (binary dependent variable: ≥ 4, < 4), and the results were 
expressed as odd ratios (ORs) and 95% confidence intervals 
(CI). p < 0.05 (two-tailed) was taken as the significance 
threshold for all the tests.
Results
Demographic and clinical variables
The ASRS v1.1 Symptom Checklist Part A was positive 
(ADHD +) in 30 (39.5%) and negative (ADHD−) in 46 
(60.5%) of the 76 included patients.
Demographic and clinical variables did not differ between 
ADHD + and ADHD− patients (Table 1).
Neuropsychological measures
Among neuropsychological measures, only executive func-
tion was significantly worse in the ADHD + (− 1.41 ± 1.62, 
median − 1.28) than the ADHD− group (− 0.48 ± 1.61, 
median − 0.27; p = 0.024), while the other domains (verbal 
memory: p = 0.78; visuospatial memory: p = 0.16; working 
memory: p = 0.83; attention: p = 0.33) did not significantly 
differ between the two groups (Fig. 2). Repeated statisti-
cal analysis with multivariate generalized linear model 
including potential covariates confirmed the significant 
ADHD + vs ADHD− difference for executive function 
Z-score (p = 0.028), while the other domains were not sig-
nificant (verbal memory: p = 0.18; visuospatial memory: 
p = 0.70; working memory: p = 0.53; attention: p = 0.12).
QoL measures
All SF-36 dimensions had lower score than the reference 
Italian population (Apolone and Mosconi 1988; Fig. 3). 
SF-36 scores were significantly lower in the ADHD + group 
than the ADHD− one for all SF-36 dimensions (PF: 
p = 0.018; RP: p = 0.021; BP: p = 0.015; GH: p = 0.009; 
VT: p = 0.027; SF: p = 0.005; RE: p = 0.011; MH: p = 0.006; 
Fig. 3).
GHQ-12 score was not significantly different between 
the two groups (ADHD + : 7.9 ± 3.7, median 8.5; ADHD−: 
7.0 ± 3.5, median 7.5; p = 0.23), with GHQ-12 score ≥ 4 
in 24 ADHD + (80.0%) and 35 (76.1%) ADHD− patients 
(p = 0.69).
Relationship between neuropsychological and QoL 
measures
Among SF-36 dimensions, only GH (Spearman’s ρ correla-
tion coefficient = 0.40, p = 0.012) and MH (Spearman’s ρ 
correlation coefficient = 0.42, p = 0.009) were significantly 
correlated with the executive function Z-score (i.e., the 
1113Adult attention‑deficit/hyperactivity disorder symptoms, cognitive dysfunction and quality…
1 3
Table 1  Demographic and 
clinical characteristics of the 
patients according to the ASRS 
v1.1 Symptom Checklist Part A
ADHD+/ADHD−: positive/negative screening for adult ADHD according to the Adult ADHD Self-Report 
Scale version 1.1 (ASRS v1.1) Symptom Checklist Part A
ADHD attention-deficit/hyperactivity disorder, BDI-II Beck Depression Inventory II, BZD benzodiazepine, 
DDDE daily diazepam dose equivalent, STAI-Y State Trait Anxiety Inventory form
a N (% of row)
b Mean ± S.D; median
c N (% of column)
ADHD+ (N = 30) ADHD− (N = 46) p value
Demographic
 Sex (men/women)a 15 (50.0%)/15 (50.0%) 19 (41.3%)/27 (58.7%) 0.46
 Ageb 41.9 ± 9.9; 41 44.1 ± 10.1; 43.5 0.23
 Education (years)b 12.0 ± 3.5; 13 13.1 ± 3.6; 13 0.34
Clinical
 BZD/Z-drug active  principlec 0.90
  Lormetazepam 19 (63.3%) 29 (63.0%)
  Zolpidem 5 (16.7%) 8 (17.4%)
  Alprazolam 3 (10.0%) 5 (10.9%)
  Clonazepam 2 (6.7%) 1 (2.2%)
  Lorazepam 1 (3.3%) 2 (4.3%)
  Triazolam 0 (0%) 1 (2.2%)
 BZD/Z-drug dosage, (DDDE, mg)b 473.5 ± 345.1; 375 367.6 ± 357.7; 250 0.23
 BZD/Z-drug use duration (months)b 125.4 ± 107.6; 78 115.6 ± 92.4; 120 0.88
 Tobacco smoke (yes/no)a 18 (60.0%)/12 (40.0%) 28 (60.9%)/18 (39.4%) 0.94
 Depression (BDI–II)b 24.4 ± 11.1; 25 26.5 ± 12.0; 30 0.28
 State anxiety (STAI-Y) 40.0 ± 5.3; 40 40.8 ± 6.7; 42 0.48
 Trait anxiety (STAI-Y) 45.7 ± 11.0; 44 44.8 ± 8.5; 45 0.87
Fig. 2  Neuropsychological 
outcomes (Z-scores) in patients 
positive (ADHD+ , black boxes) 
and negative (ADHD−, white 
boxes) to the ASRS v1.1 Symp-
tom Checklist Part A. Negative 
and positive Z-scores indicate 
worse and better performance 
than the average value of the 
normal population, respectively. 
Horizontal error bars equal 1 
S.E.M. * marks p < 0.05 for 
ADHD+ vs. ADHD– compari-
son
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worse the cognitive measure, the lower the QoL score), 
while the other cognitive domains did not influence SF-36 
scores.
Neuropsychological Z-scores did not differ in patients 
with GHQ-12 score ≥ 4 (verbal memory: − 0.20 ± 0.75; 
visuospatial memory: − 1.26 ± 1.07; working memory: 
− 1.24 ± 0.90; attention: − 0.50 ± 1.36; executive function: 
− 0.75 ± 1.69) than in those with GHQ-12 score < 4 (ver-
bal memory: − 0.47 ± 0,73, p = 0.20; visuospatial memory: 
− 1.36 ± 0.87, p = 0.69; working memory: − 1.01 ± 0.96, 
p = 0.38; attention: − 0.53 ± 1.22, p = 0.94; executive func-
tion: − 1.20 ± 1.60, p = 0.32).
Multivariate analysis
Adult ADHD, neuropsychological Z-scores, and variables 
(i.e., sex, age, education, BZD/Z-drug active principle, and 
DDDE) that we found to significantly influence QoL in high-
dose BZD/Z-drug users in previous studies (Tamburin et al. 
2017b; Lugoboni et al. 2020b) were entered as covariates in 
the multivariate analysis with QoL measures as dependent 
variables.
Positivity to adult ADHD negatively influenced (i.e., 
lower scores indicating worse QoL in ADHD + group) VT, 
SF, RE and MH; neuropsychological Z-scores significantly 
influenced (i.e., lower scores in patients with more severe 
neuropsychological measures) PF (working memory), 
RP (visuospatial memory), GH (executive function), SF 
(verbal and working memory, executive function), RE 
(visuospatial memory) and MH (executive function); age 
significantly influenced (i.e., higher scores indicating bet-
ter QoL in older patients) all SF-36 dimensions except RE; 
DDDE negatively influenced (i.e., lower scores in patients 
using higher BZD/Z-drug dosage) PF (Table 2).
The multivariate logistic regression model showed 
that verbal (OR = 0.37, 95% CI 0.15–0.87, p = 0.023) 
and working memory Z-scores (OR = 0.33, 95% CI 
0.19–0.57, p < 0.001) significantly influenced (i.e., the 
worse the Z-score, the higher the likelihood) the risk of 
GHQ-12 score ≥ 4, while the remaining covariates were 
not significant.
Discussion
The present study confirmed that (a) screening for adult 
ADHD was frequently positive, (b) QoL (SF-36) was 
worse than the general population (Tamburin et al. 2017b), 
and (c) worse in ADHD + than ADHD− patients (Lugob-
oni et al. 2020b) in high-dose BZD/Z-drug users. This 
report yielded these new findings: (d) executive function 
was significantly worse in ADHD + than ADHD− patients, 
(e) some SF-36 dimensions were negatively influenced by 
executive function Z-score, and (f) multivariate analysis 
showed a complex interplay of adult ADHD and cognitive 
dysfunction in negatively influencing QoL measures (SF-
36 and GHQ-12).
Fig. 3  SF-36 scores in patients 
positive (ADHD+ , black 
boxes) and negative (ADHD−, 
white boxes) to the ASRS v1.1 
Symptom Checklist Part A. 
The SF-36 scores ranged from 
0 (worst score) to 100 (best 
score). All the dimensions 
were significantly worse in 
ADHD+ than ADHD– patients 
(* marks p < 0.05). Horizontal 
bars indicate the median score 
in the reference Italian popula-
tion (Apolone and Mosconi 
1988). Vertical error bars equal 
1 S.E.M. ADHD attention-
deficit/hyperactivity disorder, 
BP bodily pain, GH general 
health, MH mental health, PF 
physical functioning, RE role 
emotional, RP role physical, SF 
social functioning, SF-36 Short 
Form-36, VT vitality
1115Adult attention‑deficit/hyperactivity disorder symptoms, cognitive dysfunction and quality…
1 3
Adult ADHD
Adult ADHD symptoms were overrepresented in high-
dose BZD/Z-drug users, in that 39.4% of our sample was 
positive to adult ADHD screening with the ASRS v1.1 
Symptoms Checklist Part A. This finding is in keeping 
with our previous report (Lugoboni et al. 2020b), and in 
accordance with studies in other SUD patients (van de 
Glind et al. 2013; Katzman et al. 2017), where the preva-
lence of adult ADHD symptoms was reported up to 8 times 
higher than the general population (Volkow and Swanson, 
2013). At variance with the general population (Chung 
et al. 2019), demographic variables did not differ between 
ADHD + and ADHD− groups, probably because of the 
limited age range of our sample.
Neuropsychological measures
Overall, BZD/Z-drug users showed negative Z-scores (i.e., 
worse cognitive performance than the general population) 
for all the cognitive domains.
Among neuropsychological measures, only executive 
function Z-score turned out to be significantly worse in 
ADHD + than ADHD− group. ADHD + group showed sig-
nificantly worse performances in TMT-B, a cognitive test 
assessing divided attention and set-shifting. This finding is 
in keeping with a number of previous neuropsychological 
studies. Distinct profiles of attentional functioning were 
reported, with weak differences between ADHD subgroups, 
indicating gross disturbances of various attention functions 
in adult ADHD (Tucha et al. 2008). A selective impairment 
Table 2  Linear regression 
model analysis for the SF-36 
domains
Here are reported only covariates that turned out to be significant in the multivariate linear regression anal-
ysis. Higher SF-36 scores indicate higher QoL, Adult ADHD: 0 = ADHD−, 1 = ADHD+ 
DDDE daily diazepam dose equivalent, SF-36 Short Form-36
SF-36 domains and significant covariates β 95% CI p value
Physical functioning (PF), adjusted R2 = 0.85
 Working memory (Z-score) 6.63 0.79; 12.46 0.023
 Age (years) 0.92 0.70; 1.13  < 0.001
 DDDE (mg) − 0.18 − 0.33; − 0.03 0.021
Role physical (RP), adjusted R2 = 0.71
 Visuospatial memory (Z-score) 5.21 0.96; 9.46 0.017
 Age (years) 0.22 0.07; 0.37 0.007
Bodily pain (BP), adjusted R2 = 0.77
 Age (years) 1.01 0.88; 1.13  < 0.001
General health (GH), adjusted R2 = 0.81
 Executive function (Z-score) 3.97 0.16; 8.45 0.032
 Age (years) 0.90 0.71; 1.09  < 0.001
Vitality (VT), adjusted R2 = 0.83
 Adult ADHD − 6.54 − 9.90; − 4.32 0.013
 Age (years) 0.53 0.42; 0.63  < 0.001
Social functioning (SF), adjusted R2 = 0.82
 Adult ADHD − 9.35 − 18.27; − 3.54 0.037
 Verbal memory (Z-score) 17.31 7.22; 27.38 0.001
 Working memory (Z-score) 7.75 0.22; 15.32 0.042
 Executive function (Z-score) 4.58 1.67; 7.48 0.003
 Age (years) 0.52 0.29; 0.75  < 0.001
Role emotional (RE), adjusted R2 = 0.79
 Adult ADHD − 5.55 − 12.57; − 1.45 0.021
 Visuospatial memory (Z-score) 3.71 0.89; 6.52 0.011
Mental health (MH), adjusted R2 = 0.87
 Adult ADHD − 7.11 − 20.15; − 3.24 0.008
 Executive function (Z-score) 3.77 0.52; 7.04 0.025
 Age (years) 0.86 0.71; 1.01  < 0.001
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of attentional set shifting was documented in adults with 
ADHD (Luna-Rodriguez et al. 2018). Adult ADHD patients 
were found to display deficits in set shifting with medium-to-
large effect size difference vs. controls (Rohlf et al. 2012). A 
study exploring executive function subdomains and several 
other neuropsychological functions to control for nonexecu-
tive test demands showed selective problems in inhibition 
and set shifting, but not in other executive functions subdo-
mains in adults with ADHD (Boonstra et al. 2010).
Our findings are also in accordance with a report on sub-
jective cognitive complaints of adults with ADHD, who 
perceived attention and executive function among the most 
severely impacted neuropsychological domains (Fuermaier 
et al. 2015).
The present data appear to be in contrast with previous 
studies suggesting that neuropsychological difficulties in 
adult ADHD may not be confined to executive function and 
attention (Boonstra et al. 2005), but also involve memory 
and perceptual reasoning (LeRoy et al. 2019). Indeed, a 
review of meta-analyses on cognition in ADHD suggest sub-
stantial deficits across a variety of neurocognitive domains, 
and a moderator effect of age, with larger difference in com-
parison to controls in children and adults than adolescents 
(Pievsky and McGrath, 2018). This discrepancy might be 
ascribed to the long-term use of BZDs and Z-drugs, which 
are associated with impairment of a range of neuropsycho-
logical functions (Federico et al. 2017; Crowe and Stranks, 
2018), in keeping with the extensive allosteric modulator 
effect of GABA-A receptor alpha subunits involved in cog-
nition (Tan et al. 2011). We speculate that the high-dose 
BZD/Z-drug use might have caused a consistent reduction 
of the performance in some cognitive domains and lead to a 
floor effect on Z-scores, not allowing the demonstration of a 
concomitant detrimental effect of adult ADHD.
The influence of adult ADHD and cognition on QoL
In keeping with previous studies, all SF-36 dimensions were 
worse in high-dose BZD/Z-drug users than the general popu-
lation (Tamburin et al. 2017b), and worse in ADHD+ than 
ADHD− groups (Lugoboni et al. 2020b). GHQ-12 scores did 
not differ according to the positivity to adult ADHD screen-
ing that is in contrast to a previous report from our group 
(Tamburin et al. 2017b). The main reason for the discrep-
ancy between the two studies is the stricter inclusion criteria 
(i.e., no major psychiatric disorders, alcohol use or other 
SUD) to avoid a bias effect on cognitive outcomes in the 
present report. Adult ADHD patients and high-dose BZD/Z-
drug users frequently have multiple psychiatric comorbidi-
ties (Katzman et al. 2017), which may have a higher effect 
on GHQ-12 than SF-36, because the latter provides a very 
limited coverage of themes identified by people with mental 
health problems (Brazier et al. 2014).
Lower executive function Z-scores resulted in worse GH 
and MH dimensions of SF-36 in our sample. Since this is the 
first study to explore the correlation between cognition and 
QoL in high-dose BZD/Z-drug users, our finding is difficult 
to compare to previous reports, being the effect on SF-36 
scores also related to the underlying disease and the age 
class. Indeed, similar findings were reported in a sample of 
patients with mild traumatic brain injury with a similar age 
than ours (Yousefzadeh-Chabok et al. 2019).
The multivariate model showed that adult ADHD and 
cognitive dysfunction negatively influenced QoL measures 
with a complex interplay between these factors and age. 
Positivity to adult ADHD screening negatively influenced 
VT, SF, RE and MH SF-36 components, in keeping with 
previous evidence that adult ADHD symptoms are differen-
tially related to specific aspects of QoL (Gjervan et al. 2014). 
Cognitive function impairment had a differential negative 
influence on some SF-36 dimensions, i.e., verbal memory 
influenced SF, visuospatial memory influenced RP and RE, 
working memory influenced PF and SF, and executive func-
tion influenced GH, SF and MH. Age had a positive effect 
(i.e., better QoL in older patients) on all SF-36 dimensions 
except RE and DDDE had a detrimental effect on PF only. 
These findings appear to be novel in the context of cognitive 
deficits in adult ADHD, because previous studies mainly 
focused on the effect of executive dysfunction on SF-36 out-
comes but did not explore the full range of neuropsychologi-
cal domains (Stern et al. 2017; Sjöwall and Thorell 2019).
The multivariate logistic model indicated that lower 
verbal and working memory Z-scores were associated to 
increased risk of more severe psychological distress (i.e., 
GHQ-12 score ≥ 4), in keeping with evidence that higher 
GHQ-12 score is associated with cognitive deficits (Bauer-
meister and Bunce, 2015).
Limitations
The main limitation is that adult ADHD was detected with 
the ASRS v1.1 Symptoms Checklist Part A, which is one 
of the recommended screening tools for adult ADHD in 
SUD (Crunelle et al. 2018) because of the good accuracy 
and short application time that might be important in the 
clinical setting (Dakwar et al. 2012; van de Glind et al. 
2013), but does not replace a more extensive diagnostic 
examination. Another limitation is that adult ADHD was 
not subtyped (i.e., predominantly inattentive, predomi-
nantly hyperactive-impulsive, combined), but cognitive 
dysfunctions were not reported to be consistently differ-
ent across these subtypes (Tucha et al. 2008; LeRoy et al. 
2019). Moreover, our comprehensive battery of objective 
neuropsychological tests (Tucha et al. 2015) included the 
main domains, but did not assess some ADHD−related 
behavioral features (e.g., reward responsivity, emotional 
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dysregulation, and temporal discounting) and basic pro-
cesses that have been hypothesized to contribute to higher 
order cognitive dysfunction in adult ADHD (Butzbach 
et al. 2019). Future studies should include a larger number 
of neuropsychological measures (Fuermaier et al. 2019). 
Furthermore, the absence of a control group from the gen-
eral population and a group of ADHD patients without 
concurrent use of BZD/Z-drugs may limit the interpreta-
tion of the present findings, in that we explored relative 
differences between BZD/Z-drug high-dose users with vs. 
without ADHD. Finally, BZD/Z-drug dosage and long-
term use duration had no effect on neuropsychological 
measures, suggesting that a population with larger vari-
ability (i.e., low and high dose) of BZD/Z-drugs users 
would offer further support to these findings.
Conclusion
We provided new information on the interplay between 
adult ADHD, cognitive dysfunction and QoL in in high-
dose BZD/Z-drug users. These findings underscore the 
importance of assessing adult ADHD, neuropsychologi-
cal measures and QoL in this SUD to offer a full scenario 
of these patients, who are frequently impaired in everyday 
activities (Fuermaier et al. 2017a). Moreover, they suggest 
that these outcomes should also be explored in other popu-
lations of long-term BZD/Z-drug users with neurologi-
cal and psychiatric comorbidities. Future studies should 
explore whether specific cognitive rehabilitation programs 
alongside the standard SUD treatments (i.e., psychother-
apy, pharmacotherapy, and multimodal treatment) may be 
effective on the neuropsychological impairment and QoL 
in ADHD + high-dose BZD/Z-drugs users. Whether phar-
macological treatment for ADHD with methylphenidate 
(Mattos et al. 2013; Fuermaier et al. 2017b) and BZD/Z-
drug detoxification (Soyka 2017; Tamburin et al. 2017a) 
might improve cognitive dysfunction and QoL in these 
patients is another topic for future research.
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